Therapeutic Approach

Archive: August, 2019

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update   LOS ANGELES (August 14, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial […]

Leave Your Comments »

Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board

LOS ANGELES (August 13, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal (GI) diseases, today announced the appointment of Anthony J. Lembo, M.D., to its Medical Advisory Board. “We are fortunate to have Dr. Lembo, who will […]

Leave Your Comments »

Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call

Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call Market research indicates an unmet need for better lactose intolerance treatments and interest from both patients and physicians in the RP-G28 drug profile LOS ANGELES (August 8, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD